Ph.D., Senior Vice-President Research and Development, CareDx
Biography
Dr. Woodward has led research and development projects in transplant diagnostics and gene expression discovery for over 20 years. Most recently at CareDx he was responsible for the bioinformatics, biostatistics, and laboratory teams that developed and validated AlloSure, an application of cell-free DNA to solid organ transplantation. Earlier in his career, he initiated biomarker discovery efforts with BioCardia and XDx and subsequently led the laboratory development of AlloMap, a gene expression test that has become an integral component of precise patient care in heart transplantation. During a post-doctoral fellowship at the Gladstone Institutes, Dr. Woodward developed unique methods for analysis of gene regulation in vivo to study atherosclerosis. Dr. Woodward earned his Ph.D. in physiology at the University of Missouri-Columbia with study of the coordinate regulation of gene expression in response to steroids.
Clinical Dx Showcase:
CareDx
CareDx is committed to improving transplant patient outcomes by providing innovative and intelligent solutions through the entire patient journey.
Multi-Modality Testing for Precision In Transplantation
CareDx multi-modality transplant surveillance solutions quantify graft injury and recipient immune quiescence while predicting long-term outcomes. Validation across long-term multi-center studies and registries provide physicians with reliable data to stratify individual patients in the context of real-world clinical use.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 22 2.30 P.M.-3.45 P.M.,Track 7 - January 23 1.15 P.M.-1.30 P.M.,Track 6 - January 24 9.00 A.M.-1.15 P.M.
The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
